Published in J Cutan Pathol on December 08, 2014
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood (2009) 3.63
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood (2009) 1.85
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol (2012) 1.51
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia. Asia Pac J Clin Oncol (2010) 1.40
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys (2002) 1.25
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res (2012) 1.24
Angiogenic factors in bone local environment. Cytokine Growth Factor Rev (2013) 1.23
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest (2012) 1.18
Parametric imaging of the local attenuation coefficient in human axillary lymph nodes assessed using optical coherence tomography. Biomed Opt Express (2012) 1.12
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. J Med Case Rep (2013) 1.12
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer (2004) 1.09
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
Abnormal nuclear pore formation triggers apoptosis in the intestinal epithelium of elys-deficient zebrafish. Gastroenterology (2008) 1.07
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol (2006) 1.07
Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood (2011) 1.03
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer (2013) 1.00
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol (2009) 0.99
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res (2014) 0.97
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
The R229Q mutation in NPHS2 may predispose to proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol (2008) 0.95
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer (2009) 0.94
Pseudo-tumor mimicking indwelling pleural catheter tract metastasis in mesothelioma. J Bronchology Interv Pulmonol (2014) 0.91
Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res (2013) 0.90
Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol (2013) 0.89
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol (2012) 0.89
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med (2012) 0.88
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study. Melanoma Res (2004) 0.87
Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis. Oncogene (2005) 0.86
BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid (2015) 0.86
Ultrasound-guided optical coherence tomography needle probe for the assessment of breast cancer tumor margins. AJR Am J Roentgenol (2012) 0.84
Detection of genetic alterations by immunoFISH analysis of whole cells extracted from routine biopsy material. J Mol Diagn (2007) 0.84
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 0.84
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol (2007) 0.83
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg (2009) 0.83
Quantifying spore viability of the honey bee pathogen Nosema apis using flow cytometry. Cytometry A (2013) 0.82
Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer (2014) 0.82
Small cell lung cancer presenting with paraneoplastic limbic encephalitis. Asia Pac J Clin Oncol (2011) 0.81
Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology. Br J Haematol (2014) 0.81
Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci (2012) 0.81
Relationship between inflammatory cytokines and self-report measures of training overload. Res Sports Med (2010) 0.81
Superficial CD34-positive fibroblastic tumour: report of two new cases. Pathology (2015) 0.81
Idiopathic diffuse dendriform pulmonary ossification in a dental technician. Pathology (2012) 0.78
EGFL7 is expressed in bone microenvironment and promotes angiogenesis via ERK, STAT3, and integrin signaling cascades. J Cell Physiol (2015) 0.78
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer (2008) 0.78
High-resolution melt PCR analysis for genotyping of Ureaplasma parvum isolates directly from clinical samples. J Clin Microbiol (2013) 0.78
Flow cytometry as a rapid and reliable method to quantify sperm viability in the honeybee Apis mellifera. Cytometry A (2014) 0.78
FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology (2015) 0.77
Developments in the immunophenotypic analysis of haematological malignancies. Blood Rev (2013) 0.77
Flow cytometric analysis of lymphocyte subset kinetics in Bali cattle experimentally infected with Jembrana disease virus. Vet Immunol Immunopathol (2012) 0.77
Bleeding Small Intestine Pyogenic Granuloma on 18F-FDG PET/CT. Clin Nucl Med (2015) 0.76
A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One (2010) 0.76
Histopathological features associated with application of black salve to cutaneous lesions: a series of 16 cases and review of the literature. Pathology (2013) 0.76
Gain-of-function Lyn induces anemia: appropriate Lyn activity is essential for normal erythropoiesis and Epo receptor signaling. Blood (2013) 0.76
Treatment of superior sulcus non-small cell lung cancer. Asia Pac J Clin Oncol (2010) 0.75
Sentinel node biopsy for melanoma: The medical oncology perspective. Aust Fam Physician (2015) 0.75
A case of abatacept associated neutrophilic dermatosis and a review of the literature. Australas J Dermatol (2014) 0.75
Naevus or melanoma? An inadequate paradigm for a small number of clinically important lesions. Aust Fam Physician (2017) 0.75
Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood. Br J Haematol (2006) 0.75
Is Immunohistochemical Screening of Cutaneous Leiomyomas for the Early Detection of Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome Justified? Am J Dermatopathol (2017) 0.75
Malignant Melanocytic Matricoma: A Report of 2 Cases and Review of the Literature. Am J Dermatopathol (2016) 0.75
The "Umbrella Sign": A Useful Clue in the Diagnosis of Melanocytic Lesions in Sun Damaged Skin. Am J Dermatopathol (2016) 0.75
Corrigendum: NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase. Sci Rep (2016) 0.75
Cutaneous intravascular anaplastic large T-cell lymphoma: a case report and review of the literature. Am J Dermatopathol (2012) 0.75
Pseudomelanomas Following Stevens-Johnson Syndrome. Am J Dermatopathol (2017) 0.75
Cutaneous Atypical Neurofibroma: A Case Report and Review of Literature. Am J Dermatopathol (2017) 0.75
Basal cell carcinosarcoma: a report of 4 cases and review of the literature. Am J Dermatopathol (2014) 0.75
Sox10-Positive Cells Within Scars: A Potential Diagnostic Pitfall. Am J Dermatopathol (2016) 0.75
The RCPA Quality Assurance Program in Dermatopathology: A Retrospective Review. Am J Dermatopathol (2017) 0.75
BAP1 deficient malignant melanoma arising from the intradermal component of a congenital melanocytic naevus. Pathology (2015) 0.75
Azurophilic granules in acute lymphoblastic leukaemia resulting from abundant mitochondria. Br J Haematol (2004) 0.75
Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. Pathology (2012) 0.75
Metastatic Cellular Blue Nevus: A Rare Case With Metastasis Beyond Regional Nodes. Am J Dermatopathol (2017) 0.75
Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. Am J Dermatopathol (2016) 0.75
Positive sentinel lymph node metastasis from a metastasis in Melanoma. Asia Pac J Clin Oncol (2014) 0.75
The 2004 Human Genome Variation Society scientific meeting. Hum Mutat (2005) 0.75